<DOC>
	<DOC>NCT01708889</DOC>
	<brief_summary>The purpose of this study is to determine the effect of renal impairment on pharmacokinetics (PK) of BMS-914143.</brief_summary>
	<brief_title>Pharmacokinetic Study of BMS-914143 in Participants With Normal Renal Function and Mild, Moderate, Severe and End-stage Renal Dysfunction</brief_title>
	<detailed_description>Primary purpose: Protocol designed to evaluate the effect of renal impairment on pharmacokinetics of BMS-914143</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Hepatitis B, Chronic</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>Normal renal function or mild, moderate, severe or endstage renal dysfunction History of uncontrolled or unstable cardiovascular, respiratory, gastrointestinal, hepatic, endocrine, hematopoietic, psychiatric or neurological conditions within 6 months of Lambda administration History of chronic liver disease including cirrhosis, hepatitis B virus (HBV), hepatitis C virus (HCV), primary biliary cirrhosis, etc History of central nervous system or neuropsychiatric disease. Subjects with severe depression and/or other uncontrolled psychiatric conditions should not be enrolled in this study History of of suicide attempt within the 5 years preceding BMS914143 administration Inability to tolerate subcutaneous injections Donation of &gt;400 mL of blood within 8 weeks or plasma within 4 weeks of planned dosing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>